(NYSE: LLY) Eli Lilly & Co's forecast annual revenue growth rate of 19.04% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Eli Lilly & Co's revenue in 2025 is $59,419,800,000.On average, 31 Wall Street analysts forecast LLY's revenue for 2026 to be $73,176,484,326,828, with the lowest LLY revenue forecast at $63,822,857,435,070, and the highest LLY revenue forecast at $81,913,721,009,022. On average, 26 Wall Street analysts forecast LLY's revenue for 2027 to be $85,637,587,627,845, with the lowest LLY revenue forecast at $71,125,001,574,138, and the highest LLY revenue forecast at $99,530,001,936,960.
In 2028, LLY is forecast to generate $93,561,794,279,019 in revenue, with the lowest revenue forecast at $74,770,401,341,130 and the highest revenue forecast at $107,867,341,289,943.